Exclusive agreement in North America marks first line of vascular access dressings from CareFusion
CHICAGO - Wednesday, November 20th 2013 [ME NewsWire]
(BUSINESS WIRE) Vancive Medical Technologies™ and CareFusion Corporation (NYSE:CFN) today announced an exclusive agreement in the United States, Canada and Mexico for the licensing and distribution of Vancive’s BeneHold™ Chlorhexidine Gluconate (CHG) antimicrobial Adhesive Technology for applications in vascular access.
Under the agreement, CareFusion will market Vancive’s unique antimicrobial adhesive technology used with transparent dressings that are ideally suited for protection of catheter insertion sites. The first product received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in September 2012 and will be co-branded under CareFusion’s new ChloraShield™ brand.
“We are excited about this collaboration, and believe it is an excellent opportunity to combine the unique capabilities of each company,” said Howard Kelly, president and general manager of Vancive Medical Technologies. “By bringing together the considerable infection prevention expertise at CareFusion and Vancive’s cutting-edge technologies, we will provide innovative solutions to the vascular access market.”
CareFusion and Vancive are working together to develop a comprehensive line of dressing products that incorporate the BeneHold™ CHG antimicrobial Adhesive Technology to meet the specific needs associated with many types of vascular access procedures. CareFusion expects to commercialize these offerings during the company’s fiscal third quarter, which begins in April.
“The collaboration with Vancive Medical Technologies and the new ChloraShield™ line of dressings are a perfect fit with our leadership in CHG products,” said Jim Leitl, senior vice president and general manager of Medical Specialties at CareFusion. “These innovative vascular access dressings extend our clinically differentiated infection prevention and vascular access product portfolios, allowing us to create greater value for our customers.”
BeneHold is a trademark of Avery Dennison Corporation. ChloraShield is a trademark of CareFusion Corporation.
About Vancive Medical Technologies
Vancive Medical Technologies makes inspired advances that lead to intelligent results. The business uses the most advanced adhesive and material technologies to create products that make healthcare easier for everyone. Vancive Medical Technologies is an Avery Dennison business headquartered in Chicago, Illinois. To learn more about Vancive Medical Technologies, visit www.vancive.averydennison.com.
About Avery Dennison
Avery Dennison (NYSE:AVY) is a global leader in labeling and packaging materials and solutions. The company’s applications and technologies are an integral part of products used in every major market and industry. With operations in more than 50 countries and 30,000 employees worldwide, Avery Dennison serves customers with insights and innovations that help make brands more inspiring and the world more intelligent. Headquartered in Pasadena, California, the company reported sales from continuing operations of $6 billion in 2012. Learn more at www.averydennison.com.
CareFusion (NYSE:CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops industry-leading technologies including Alaris® infusion pumps, Pyxis® automated dispensing and patient identification systems, AVEA®, AirLife® and LTV®series ventilation and respiratory products, ChloraPrep® products, MedMined® services for data mining surveillance, V. Mueller® surgical instruments, and an extensive line ofproducts that support interventional medicine. CareFusion employs approximately 15,000 people across its global operations. More information may be found atwww.carefusion.com.
Vancive Media Contact
T: +1 610-328-1051
Vancive Marketing Communications Contact
T: + 1 312-629-4607
CareFusion Media Contact
T: +1 858-617-2361
CareFusion Investor Contact
T: +1 858-617-1203
Post a Comment